20亿美元押注三靶点GLP-1,诺和诺德继续买买买

新浪医药
25 Mar

近日,跨国制药巨头诺和诺德与 联邦制药 (03933.HK)全资附属公司联邦生物达成一份金额最高达20亿美元的独家许可协议。根据许可协议,诺和诺德将获得一款在研减肥药物UBT251在中国大陆及港澳台地区以外的全球范围内开发、生产及商业化独家权利。与此同时,联邦生物将获得2亿美元首付款,最高达18亿美元的潜在里程碑付款,以及在中国大陆及港澳台地区外基于净销售额的分级特许权使用费。即使在中国 创新药 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10